Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard A Burris

Showing results (111-120 of 247) with videos related to

Pageof 25
Sort By:
British Journal of Cancer|January 29, 2024
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumoursHoward A Burris, Jordan Berlin, Tobias Arkenau, et al.
Cancer|November 21, 2014
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumorsJohanna C Bendell, Manish R Patel, Jeffrey R Infante, et al.
Cancer|September 1, 2005
A Phase I trial of protracted oral fixed-dose temozolomideSuzanne F Jones, F Anthony Greco, Victor G Gian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinomaHoward A Burris, Lee S Rosen, Caio M Rocha-Lima, et al.
Investigational New Drugs|April 17, 2013
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumorsSunil Sharma, Elisabeth G de Vries, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2019
Challenges with Novel Clinical Trial Designs: Master ProtocolsMichael Cecchini, Eric H Rubin, Gideon M Blumenthal, et al.
Expert Review of Anticancer Therapy|June 28, 2021
The evolution of cyclin dependent kinase inhibitors in the treatment of cancerKomal Jhaveri, Howard A Burris Rd, Timothy A Yap, et al.
Cancer Biology & Therapy|January 30, 2013
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trialJeffrey R Infante, Hendrik-Tobias Arkenau, Johanna C Bendell, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)David R Spigel, Mark S Rubin, Victor G Gian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2014
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancerKathy D Miller, Véronique Diéras, Nadia Harbeck, et al.
Pageof 25

Showing results (111-120 of 247) with videos related to

Sort By:
Pageof 25
British Journal of Cancer|January 29, 2024
A phase I study of ATR inhibitor gartisertib (M4344) as a single agent and in combination with carboplatin in patients with advanced solid tumoursHoward A Burris, Jordan Berlin, Tobias Arkenau, et al.
Cancer|November 21, 2014
Phase 1, open-label, dose escalation, safety, and pharmacokinetics study of ME-344 as a single agent in patients with refractory solid tumorsJohanna C Bendell, Manish R Patel, Jeffrey R Infante, et al.
Cancer|September 1, 2005
A Phase I trial of protracted oral fixed-dose temozolomideSuzanne F Jones, F Anthony Greco, Victor G Gian, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 25, 2010
Phase 1 experience with an anti-glycotope monoclonal antibody, RAV12, in recurrent adenocarcinomaHoward A Burris, Lee S Rosen, Caio M Rocha-Lima, et al.
Investigational New Drugs|April 17, 2013
Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumorsSunil Sharma, Elisabeth G de Vries, Jeffrey R Infante, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 31, 2019
Challenges with Novel Clinical Trial Designs: Master ProtocolsMichael Cecchini, Eric H Rubin, Gideon M Blumenthal, et al.
Expert Review of Anticancer Therapy|June 28, 2021
The evolution of cyclin dependent kinase inhibitors in the treatment of cancerKomal Jhaveri, Howard A Burris Rd, Timothy A Yap, et al.
Cancer Biology & Therapy|January 30, 2013
Lenalidomide in combination with gemcitabine as first-line treatment for patients with metastatic carcinoma of the pancreas: a Sarah Cannon Research Institute phase II trialJeffrey R Infante, Hendrik-Tobias Arkenau, Johanna C Bendell, et al.
Lung Cancer (Amsterdam, Netherlands)|November 8, 2017
Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI)David R Spigel, Mark S Rubin, Victor G Gian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 16, 2014
Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancerKathy D Miller, Véronique Diéras, Nadia Harbeck, et al.
Pageof 25